# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-02-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He wants to keep working at his gym and stay strong **S**
- He worries about the cost of new medicines **S**
- He wants to know whether the blows he took in the ring will affect his memory **S**

## Your goals

- A1c below 7% within six to nine months, without low blood sugar. Target: 2008-09-14. Recorded outcome: 8.4% to 6.8% at seven months; no low blood sugar. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home. Target: 2008-09-14. Recorded outcome: 122/76 in the clinic; home average 124/78. **S**
- LDL cholesterol below 70 mg/dL. Target: 2008-04-13. Recorded outcome: 132 to 68 mg/dL on atorvastatin. **S**
- Weight loss of 7 to 10% for liver health within a year. Target: 2008-09-14. Recorded outcome: 104.0 to 97.2 kg (6.5%) at seven months. **S**
- Liver cancer surveillance by ultrasound with AFP every six months, on time. Target: 2008-09-14. Recorded outcome: Baseline and six-month ultrasounds with AFP on schedule; no focal lesion; AFP 4.2 and 4.0 ng/mL. **S**
- No alcohol, to protect the liver. Target: 2008-09-14. Recorded outcome: No alcohol since the two-week visit. **S**

## What we agreed to do

- Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same day. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023) **S**
- Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Compensated cirrhosis: liver ultrasound with AFP every six months for hepatocellular carcinoma surveillance, upper endoscopy to screen for varices, hepatitis A and B and pneumococcal vaccines, no alcohol, no NSAIDs, acetaminophen no more than 2 g a day, and teaching on the warning signs of decompensation. Guideline: AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Semaglutide once weekly, increased every four to eight weeks as tolerated, for its cardiovascular and kidney benefit, weight and steatotic liver disease; prior authorization and the manufacturer's assistance program handled by the clinic. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023) **S**
- Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Amlodipine added to lisinopril and increased to reach the goal, with ankle-swelling checks. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026) **S**
- Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life. Guideline: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine. Guideline: 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026) **S**

## Follow-up

- 2008-02-16: Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer **S**
- 2008-03-02: Two-week review of home blood pressure readings, with liver elastography, a liver ultrasound and the hepatology consultation **S**
- 2008-04-13: Eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines **S**
- 2008-05-18: Three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination **S**
- 2008-07-13: Periodic adult preventive visit **S**
- 2008-09-14: Seven-month review: six-month liver cancer surveillance ultrasound and AFP, A1c, kidney function, urine albumin and vaccines **S**

This teaching document does not replace care from a qualified clinician.
